No Data
No Data
Express News | Lantern Pharma Inc - Phase 1B/2a Trial for Recurrent GBM to Start Late 2024
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma From the FDA
Express News | Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma From the FDA
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ...
Lantern Appoints Piers Dixon as Head of Sales
Lantern Pharma Says FDA Oks Rare Pediatric Disease Designations In MRT, RMS, And Hepatoblastoma
No Data
No Data
jimmy the trader : $China Pharma (CPHI.US)$ broths